Over the course of 2018, The Center for Biosimilars® provided coverage of conferences in the United States and abroad. Here is a look at our top 5 conference coverage articles from 2018.
Over the course of 2018, The Center for Biosimilars® provided coverage of conferences in the United States and abroad. Here is a look at our top 5 conference coverage articles from 2018.
5. Once Educated, Patients Generally Receptive to Switching to Biosimilars
At the European League Against Rheumatism’s Annual European Congress of Rheumatology, the patient experience with switching to biosimilars from their reference products was a key topic among stakeholders.
In Australia, researchers reported that patients with rheumatoid arthritis have proven to be receptive to the idea of switching to a biosimilar medicine if their physician recommends doing so. In a single center in the Netherlands, patients reported on how useful the information they were provided about the switch was to them.
4. Lessons From European Biosimilars: Where Have We Been, and Where Are We Going?
During the SMi 9th Annual Biosimilars and Biobetters Conference in the United Kingdom, stakeholders gathered to discuss the state and trajectory of the European Union biosimilars marketplace.
In the early days of the market, said Michael Muenzberg, MD, biosimilar developers had to decide between 2 business models, which he termed a “follow-on model” and a “biogeneric model.” The former involves investing in device design, safety data, and sales and marketing to compete on aspects other than price alone. The latter model, which has not emerged as a dominant option in Europe, is simply to make a product as cheap as possible.
3. Biosimilar Beats Subcutaneous Rituximab on Cost Savings in NHL
The launch of biosimilar rituximab is anxiously anticipated among US healthcare stakeholders who hope to bring down the high cost of intravenously (IV) administered rituximab in the treatment of non-Hodgkin lymphoma (NHL). However, another innovation in rituximab delivery—a subcutaneously administered rituximab formulation—has the potential to save both time and cost.
During the 60th American Society of Hematology Annual Meeting and Exposition, researchers presented findings from a time-and-cost simulation of subcutaneous rituximab (Rituxan Hycela), brand-name IV rituximab (Rituxan), and biosimilar IV rituximab from the US payer perspective.
2. FDA’s Leah Christl Provides an Agency Perspective on the Biosimilars Landscape
Over time, the United States will see a dramatic increase in the number of biosimilar approvals based on the quantity of applications that the FDA is currently receiving, said Leah Christl, PhD, associate director for therapeutic biologics at the Office of New Drugs in the FDA’s Center for Drug Evaluation and Research, during the National Policy and Advocacy Summit on Biologics and Biosimilars.
1. Researchers Report Findings on 3 Biosimilar Trastuzumab Products
During the 2018 American Society of Clinical Oncology’s Annual Meeting, researchers presented findings on 3 biosimilar trastuzumab products: Samsung Bioepis’ SB3, Amgen’s ABP 980, Biocad’s Herticad.
Cordavis Report Outlines Strategies for Biosimilar Development, Access in the US Health Care Market
May 8th 2024Cordavis, a CVS Healthspire company, released a report detailing the current hurdles faced in developing and commercializing biosimilars in the US and highlighting efforts by the organization to enhance access and affordability for these products.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Review: Product Attributes Relevant to Injection-Site Pain, Adalimumab Treatment
May 4th 2024A review article summarizes the product attributes of reference and biosimilar adalimumab products, such as formulation with or without citrate, delivery volume, and needle gauge, relevant to patients’ experience of injection-site pain.
Cencora Analysis Shows Differences in Payer Coverage Between G-CSF Biosimilars
May 2nd 2024Data from a Cencora study showed some misalignment in payer coverage of granulocyte colony-stimulating factor (G-CSF) biosimilars, highlighting that while filgrastim biosimilars are often favored over the originator, reference pegfilgrastim still dominates over its biosimilars.